Claims for Patent: 9,206,251

Summary for Patent: 9,206,251

Title:	Nucleic acids encoding anti-C5 antibodies having improved pharmacokinetics
Abstract:	The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Inventor(s):	Andrien, Jr.; Bruce A. (Guilford, CT), Sheridan; Douglas L. (Branford, CT), Tamburini; Paul P. (Kensington, CT)
Assignee:	Alexion Pharmaceuticals, Inc. (Cheshire, CT)
Application Number:	14/789,329
Patent Claims:	1. A nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to complement component human C5 comprising the amino acid sequence depicted in SEQ ID NO:12. 2. A nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to complement component human C5 comprising the amino acid sequences depicted in SEQ ID NOs: 12 and 8, respectively. 3. A nucleic acid encoding a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to complement component human C5 comprising the amino acid sequence depicted in SEQ ID NO:12. 4. A nucleic acid encoding heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to complement component human C5 comprising the amino acid sequences depicted in SEQ ID NOs: 12 and 8, respectively. 5. A nucleic acid encoding a heavy chain polypeptide of an antibody, or antigen-binding fragment thereof, that binds to complement component human C5 comprising the amino acid sequence depicted in SEQ ID NO: 14. 6. A nucleic acid encoding a heavy chain polypeptide and a light chain polypeptide of an antibody, or antigen-binding fragment thereof, that binds to complement component human C5, wherein the heavy chain polypeptide comprises the amino acid sequence depicted in SEQ ID NO: 14 and the light chain polypeptide comprises the amino acid sequence depicted in SEQ ID NO: 11. 7. A vector comprising the nucleic acid according to claim 1. 8. An expression vector comprising the nucleic acid according to claim 1. 9. A cell comprising the expression vector according to claim 8. 10. A method for producing an antibody, or antigen-binding fragment thereof, that binds to complement component human C5, the method comprising culturing the cell of claim 9 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid. 11. The method of claim 10, further comprising isolating the antibody, or antigen-binding fragment thereof. 12. A vector comprising the nucleic acid according to claim 2. 13. An expression vector comprising the nucleic acid according to claim 2. 14. A cell comprising the expression vector according to claim 13. 15. A method for producing an antibody, or antigen-binding fragment thereof, that binds to complement component human C5, the method comprising culturing the cell of claim 14 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid. 16. The method of claim 15, further comprising isolating the antibody, or antigen-binding fragment thereof. 17. A vector comprising the nucleic acid according to claim 3. 18. An expression vector comprising the nucleic acid according to claim 3. 19. A cell comprising the expression vector according to claim 18. 20. A method for producing an antibody, or antigen-binding fragment thereof, that binds to complement component human C5, the method comprising culturing the cell of claim 19 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid. 21. The method of claim 20, further comprising isolating the antibody, or antigen-binding fragment thereof. 22. A vector comprising the nucleic acid according to claim 4. 23. An expression vector comprising the nucleic acid according to claim 4. 24. A cell comprising the expression vector according to claim 23. 25. A method for producing an antibody, or antigen-binding fragment thereof, that binds to complement component human C5, the method comprising culturing the cell of claim 24 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid. 26. The method of claim 25, further comprising isolating the antibody, or antigen-binding fragment thereof. 27. A vector comprising the nucleic acid according to claim 5. 28. An expression vector comprising the nucleic acid according to claim 5. 29. A cell comprising the expression vector according to claim 28. 30. A method for producing an antibody, or antigen-binding fragment thereof, that binds to complement component human C5, the method comprising culturing the cell of claim 29 under conditions and for a time sufficient to allow expression by the cell of the antibody encoded by the nucleic acid. 31. The method of claim 30, further comprising isolating the antibody, or antigen-binding fragment thereof. 32. A vector comprising the nucleic acid according to claim 6. 33. An expression vector comprising the nucleic acid according to claim 6. 34. A cell comprising the expression vector according to claim 33. 35. A method for producing an antibody, or antigen-binding fragment thereof, that binds to complement component human C5, the method comprising culturing the cell of claim 34 under conditions and for a time sufficient to allow expression by the cell of the antibody encoded by the nucleic acid. 36. The method of claim 35, further comprising isolating the antibody, or antigen-binding fragment thereof.

Details for Patent 9,206,251

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	ULTOMIRIS	ravulizumab-cwvz	Injection	761108	12/21/2018		2034-03-07
Alexion Pharmaceuticals, Inc.	ULTOMIRIS	ravulizumab-cwvz	Injection	761108	10/09/2020		2034-03-07

International Patent Family for US Patent 9,206,251

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015134894
United States of America	9803007
United States of America	9663574
United States of America	9371377
United States of America	9107861
United States of America	9079949
United States of America	2020157200